PSUSA/00010473/202503

PSUSA/00010473/202503

Human medicines European public assessment report (EPAR): Fabhalta, iptacopan, Date of authorisation: 17/05/2024, Revision: 6, Status: Authorised

Human medicines European public assessment report (EPAR): Attrogy, diflunisal, Date of authorisation: 17/07/2025, Revision: 1, Status: Authorised

Human medicines European public assessment report (EPAR): Replagal, agalsidase alfa, Date of authorisation: 03/08/2001, Revision: 30, Status: Authorised

Human medicines European public assessment report (EPAR): Tuzulby, methylphenidate hydrochloride, Date of authorisation: 28/02/2025, Revision: 2, Status: Authorised

Human medicines European public assessment report (EPAR): Leflunomide medac, leflunomide, Date of authorisation: 27/07/2010, Revision: 25, Status: Authorised

PSUSA/00002688/202503

PSUSA/00002656/202502

Emer Cooke, EMA’s Executive Director: 2025 achievements in medicine regulation